Introduction While the liraglutide effect and action in diabetes (LEAD-6) clinical trial compared the efficacy and security of liraglutide once daily (LIRA) to exenatide twice daily (EXEN) in adult individuals with type 2 diabetes, few studies have explored the associated per-patient costs of glycemic goal achievement of their use inside a real-world clinical setting. captured… Continue reading Introduction While the liraglutide effect and action in diabetes (LEAD-6) clinical